Stockscreener 앱 받기
434.31
0.52%
-2.27
시간 외 거래:
434.00
-0.31
-0.07%
전일 마감가:
$436.58
열려 있는:
$436.79
하루 거래량:
1.22M
Relative Volume:
0.93
시가총액:
$110.23B
수익:
$12.34B
순이익/손실:
$4.34B
주가수익비율:
25.75
EPS:
16.8685
순현금흐름:
$3.71B
1주 성능:
-3.12%
1개월 성능:
-1.56%
6개월 성능:
+3.15%
1년 성능:
-1.44%
1일 변동 폭
$433.15
$444.32
1주일 범위
$430.25
$456.68
52주 변동 폭
$362.50
$507.92
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
434.31 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
630.30 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.77 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.30 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.30 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 업그레이드 | Maxim Group | Hold → Buy |
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-03-10 | 재확인 | Oppenheimer | Outperform |
| 2026-02-13 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 개시 | Raymond James | Mkt Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals Insider Sold Shares Worth $613,971, According to a Recent SEC Filing - Moomoo
Vertex (VRTX) CSO Mark Bunnage sells 33 shares in pre-set 10b5-1 trade - Stock Titan
Vertex Pharmaceuticals Incorporated (VRTX) Latest Stock News & Headlines - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo! Finance Canada
Vertex Pharma stock (US92532F1003): cystic fibrosis leader after solid quarterly results - AD HOC NEWS
North Dakota State Investment Board Buys Shares of 8,821 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Canada Post Corp Registered Pension Plan Has $2.94 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock (US92532F1003): focus on cystic fibrosis and expanding pipeline - AD HOC NEWS
Vertex Pharma stock (US92532F1003): institutional flows and pipeline keep focus on biotech heavyweig - AD HOC NEWS
Vertex Pharmaceuticals stock (US92532F1003): gene-editing hopes meet kidney data buzz - AD HOC NEWS
Leuthold Group LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
STF Management LP Lowers Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (VX1.DE) Stock Price, News, Quote & History - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX.VI) Stock Price, News, Quote & History - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by DNB Asset Management AS - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Allworth Financial LP Has $6.36 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vertex Pharma stock (US92532F1003): Q1 numbers, ESOP shelf and gene-editing momentum draw investor f - AD HOC NEWS
Vertex Pharmaceuticals (NASDAQ: VRTX) insider files Form 144 to sell vested shares - Stock Titan
Mark Bunnage sells shares at VRTX (NASDAQ: VRTX) in Form 144 filing - Stock Titan
FY2027 Earnings Forecast for VRTX Issued By Erste Group Bank - MarketBeat
Daiwa Securities Adjusts PT on Vertex Pharmaceuticals to $555 From $561, Maintains Buy Rating - marketscreener.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Atria Investments Inc - MarketBeat
Layoff Tracker: Takeda cuts 4,500, Novartis lays off biomedical research staff - BioSpace
Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Carmen Bozic Sells 6,988 Shares - MarketBeat
Vertex (VRTX) CMO Carmen Bozic sells 6,988 shares in planned 10b5-1 trade - Stock Titan
Capital World Investors (NASDAQ: VRTX) reports 10.1% stake in Vertex - Stock Titan
Vertex Pharmaceuticals stock (US92532F1003): Shareholder approval fuels biotech momentum - AD HOC NEWS
Capital Research discloses 21.1M-share stake in Vertex (NASDAQ: VRTX) - Stock Titan
Vertex Pharma stock (US92532F1003): Shares up 1.06% to $453 amid biotech strength - AD HOC NEWS
Vertex Pharmaceuticals posts mixed Q1; investors focus on non-CF pipeline for growth - MSN
Pacer Advisors Inc. Buys 9,641 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Sells 10,154 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Baader Bank Aktiengesellschaft Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Fierce Biotech Layoff Tracker 2026: Takeda takes away 4.5K roles; Valneva reduces workforce - Fierce Biotech
Vertex Pharmaceuticals (VRTX) Announces Approval of 2026 Stock a - GuruFocus
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex (NASDAQ: VRTX) investors back 2026 stock plan and written consent right - Stock Titan
Vertex Pharma stock (US92532F1003): Rockets 3.77% on strong options volume - AD HOC NEWS
Crossmark Global Holdings Inc. Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Q2 2026 earnings preview - MSN
Carmen Bozic sells 2,329 VRTX shares on 02/27, 03/13 and 03/27 (VRTX) - Stock Titan
Why is Vertex Pharmaceuticals stock rallying today? - Investing.com
Why is Vertex Pharmaceuticals stock rallying today? By Investing.com - Investing.com Canada
Vertex Pharma stock (US92532F1003): Earnings highlight pain drug advances - AD HOC NEWS
Vertex’s Germany CASGEVY Deal Highlights Growing Non CF Growth Story - Yahoo Finance
A year after Vertex’s big launch, pain drug research faces a pivotal moment - BioPharma Dive
Provident Investment Management Inc. Has $67.67 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.10%
자본화:
|
볼륨(24시간):